Ruth Ralbag - ICL Israel External Independent Director
| ICL Stock | USD 4.63 0.01 0.22% |
Director
Ms. Ruth Ralbag serves External Independent Director at ICLIsrael Chemicals Ltd. since January 10, 2018. Her work experience includes the following roles Chief Financial Officer of Shaare Zedek Medical Center in Jerusalem, Deputy Director of Medical Finance at the Tel Aviv Sourasky Medical Center, Deputy Director General of Planning, Budget and Pricing at Israel Ministry of Health, Vice President and Head of Commercial and Retail Banking division at FIBI, Acting Chairperson of the Board at FIBI Mortgages Ltd., Acting Chairperson of the Board at Atzmaut Mortgage Bank Ltd. and Director at a variety of additional companies. She holds Directorship in various other companies. She holds a Bachelors degree in Economics and Business Administration and a Masters degree in Public Policy, both from The Hebrew University of Jerusalem. since 2018.
| Age | 59 |
| Tenure | 6 years |
| Address | Millenium Tower, Tel Aviv, Israel, 6107025 |
| Phone | 972 3 684 4400 |
| Web | https://www.icl-group.com |
ICL Israel Management Efficiency
The company has Return on Asset of 0.0418 % which means that on every $100 spent on assets, it made $0.0418 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0776 %, implying that it generated $0.0776 on every 100 dollars invested. ICL Israel's management efficiency ratios could be used to measure how well ICL Israel manages its routine affairs as well as how well it operates its assets and liabilities. At this time, ICL Israel's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.06. At this time, ICL Israel's Asset Turnover is quite stable compared to the past year.Similar Executives
| Found 10 records | DIRECTOR Age | ||
| Gretchen Watkins | The Mosaic | 51 | |
| Kelvin Westbrook | The Mosaic | 64 | |
| Luciano Pires | The Mosaic | 50 | |
| Nancy Cooper | The Mosaic | 66 | |
| Oscar Bernardes | The Mosaic | 73 | |
| Emery Koenig | The Mosaic | 64 | |
| Denise Johnson | The Mosaic | 53 | |
| David Seaton | The Mosaic | 59 | |
| Timothy Gitzel | The Mosaic | 57 | |
| Steven Seibert | The Mosaic | 64 | |
Management Performance
| Return On Equity | 0.0776 | ||||
| Return On Asset | 0.0418 |
ICL Israel Chemicals Leadership Team
Elected by the shareholders, the ICL Israel's board of directors comprises two types of representatives: ICL Israel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ICL. The board's role is to monitor ICL Israel's management team and ensure that shareholders' interests are well served. ICL Israel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ICL Israel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Raviv Zoller, President, Chief Executive Officer | ||
| Nitzan Moshe, Executive Vice President - ICL Global Operations | ||
| Tzipi OzerArmon, Independent Director | ||
| Dafna Gruber, External Independent Director | ||
| Lilach GevaHarel, Senior Vice President and Global General Counsel | ||
| Avisar Paz, Director | ||
| Yoav Doppelt, Executive Chairman of the Board | ||
| Ilana Fahima, Executive Vice President ICL Global Human Resources | ||
| Raviv CPA, President CEO | ||
| Ido Lilian, Executive Vice President-Global Procurement | ||
| Reem Aminoach, Independent Director | ||
| Gadi Lesin, Independent Director | ||
| Ruth Ralbag, External Independent Director | ||
| Noam Goldstein, Executive Vice President - Operational Excellence, Energy, and Innovation | ||
| Anantha Desikan, Executive Vice President, ICL Chief Innovation and Technology Officer | ||
| Maya Grinfeld, Vice Communications | ||
| Meir Mergi, President - Potash Division | ||
| Aviram Lahav, Chief Financial Officer | ||
| Chris Millington, Executive Vice President - Food and Specialties for the Phosphate Solutions division | ||
| Peggy Tharp, Vice Relations | ||
| Aya Landman, Company VP | ||
| Ofer Lifshitz, President, ICL Phosphate Solutions Division | ||
| Lior Reitblatt, Independent Director | ||
| Nadav Kaplan, Independent Director | ||
| Kobi Altman, CFO, Executive Vice President | ||
| Anat TalKtalav, President ICL Industrial Products Division | ||
| Eli Amon, Executive Vice President ICL Innovative Ag Solutions Division | ||
| Aviad Kaufman, Director | ||
| Miri Mishor, Senior Vice President - ICL Global Information Technology | ||
| Ovadia Eli, External Director | ||
| Amir Meshulam, Senior Vice President Global Internal Auditor | ||
| Advocate GevaHarel, Executive Counsel | ||
| Elad Aharonson, Executive Vice President ICL Innovative Ag Solutions Division | ||
| Miriam Haran, External Independent Director | ||
| Sagi Kabla, Director |
ICL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ICL Israel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0776 | ||||
| Return On Asset | 0.0418 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 7.81 B | ||||
| Shares Outstanding | 1.29 B | ||||
| Shares Owned By Insiders | 44.05 % | ||||
| Shares Owned By Institutions | 26.42 % | ||||
| Number Of Shares Shorted | 1.08 M | ||||
| Price To Earning | 918.89 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ICL Israel Chemicals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Fertilizers & Agricultural Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ICL Israel. If investors know ICL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ICL Israel listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.18) | Dividend Share 0.2 | Earnings Share 0.31 | Revenue Per Share 5.373 | Quarterly Revenue Growth (0.06) |
The market value of ICL Israel Chemicals is measured differently than its book value, which is the value of ICL that is recorded on the company's balance sheet. Investors also form their own opinion of ICL Israel's value that differs from its market value or its book value, called intrinsic value, which is ICL Israel's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ICL Israel's market value can be influenced by many factors that don't directly affect ICL Israel's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ICL Israel's value and its price as these two are different measures arrived at by different means. Investors typically determine if ICL Israel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ICL Israel's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.